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Abstract 
Databases devoted stricto sensu to cancer cytogenetics are the "Mitelman Database of Chromosome Aberrations 
and Gene Fusions in Cancer" (http://cgap.nci.nih.gov/Chromosomes/Mitelman), the "Atlas of Genetics and 
Cytogenetics in Oncology and Haematology" (http://atlasgeneticsoncology.org), and COSMIC 
(http://cancer.sanger.ac.uk/cosmic). However, cancer being a complex multi-step process, cytogenetics are 
broaden to "cytogenomics", with complementary resources, including resources on proteins and cancer. These 
resources are essential to both practical and theoretical knowledge in cytogenomics of cancer. Must be briefly 
reviewed: general databases (nucleic acid and protein sequences databases and bibliographic ones), cancer 
genomic portals associated to recent international integrated programs, such as TCGA or ICGC, fusion genes 
databases, genomic sequences and transcripts databases (with different cartography browsers), array CGH 
databases and structural variation databases for copy number, polymorphisms and mutation databases, databases 
on proteins (structure and function with implication of mutations and rearrangements), databases on diseases, 
databases and books on pathology, cancers, and patient associations and interfaces between science and patients. 
Other resources such as the International System for Human Cytogenetic Nomenclature (ISCN), the International 
Classification of Diseases for Oncology (ICD-O), the Human Gene Nomenclature Database (HGNC), and the 
Nomenclature for the description of sequence variations allow a common language. Data within the 
scientific/medical community should be freely available. However, most of the institutional stakeholders are now 
gradually disengaging, and well known databases are forced to beg or to disappear (which may happen!).  
Keywords: Cytogenetic, Cancer, Database, Mitelman Database, Atlas of Genetics and Cytogenetics in Oncology 
and Haematology, COSMIC, PubMed, GenBank, TCGA, ICGC, UniProt, OMIM, IARC, ISCN, ICD-O, HGNC. 
INTRODUCTION 
In each cancer case there is a genetic event present 
(Stratton MR et al., 2009). Cytogenetics has been a 
major player in understanding genetics behind 
cancer, providing specific keys for diagnosis and 
prognostic assessments, as well as enabling the sub-
classification of otherwise seemingly identical 
disease entities (Mertens F et al., 2015). This "Deep 
Insight is dedicated to cytogenetics resources will 
highlight the various facets used in the current 
strategies in theoretical understanding of cancer and 
the consequent practical strategies in treating the 
disease.  
Brief history 
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In 1914, Boveri stated that the heritable acquired 
characteristics of cancer cells are brought about by a 
disturbance of the normal chromosomal balance 
(Boveri, 1914). This theory was supported by a 
wealth of experimental data showing that cancer 
originates in a single cell through acquired genetic 
changes. The investigation in the 1950s, on ascites 
tumors that were induced experimentally or 
observed in patients tended to confirm that 
cytogenetic aberrations are an important and integral 
part of tumor development and evolution. These 
cytogenetic studies demonstrated that certain laws 
could direct neoplasia-associated chromosomal 
variability. Like selective pressures, where any 
changes in the surrounding tumor would modify the 
equilibrium, causing a change where the most viable 
chromosomal profile is prevailing in the new 
environment.  
The importance of cytogenetics boomed since the 
discovery of the first chromosomal anomaly reported 
by Peter Nowell and David Hungerford in 1960, 
linking the Philadelphia (Ph) chromosome to chronic 
myeloid leukaemia (CML) (Nowell and Hungerford, 
1960). It was the first assessment in detecting 
chromosomal anomaly in human leukaemia and 
seemed reasonable that it was the cause of origin for 
CML. This discovery was the first strong assessment 
to Boveris theory. This observation stimulated the 
field to find other karyotypic anomalies in other 
cancers. Unfortunately, a heterogenous panel of 
chromosomal rearrangements was detected in what 
seemed to be the same cancer. This was a terrible 
setback for the arguments stating karyotypic 
anomalies as the origin of cancer. The explanation 
was that chromosomal rearrangements were an 
epiphenomenon that could appear during tumor 
progression without having any pathogenetic 
consequences. 
In the 1970's the situation changed dramatically 
when chromosomal banding techniques invented by 
Caspersson and Zech (Caspersson T et al., 1970) 
were introduced. This process gave an option to 
identify individual chromosomes, which were 
defined by a unique banding pattern. The description 
of chromosomal rearrangements immediately 
became clearer providing more gravity to the 
conclusions drawn. This was a new era for cancer 
cytogenetics showing an increase in the numbers of 
aberrant human malignant and benign karyotypes. 
In the 1980s, the onset of molecular genetics 
techniques intensely widened our understanding of 
the pathogenetic progression underlying the 
neoplastic process. These techniques provided an 
opportunity to characterise the chromosomal 
breakpoints at the molecular level and has 
highlighted two classes of genes implicated in these 
karyotypical rearrangements: the oncogenes and the 
tumor suppressing genes. 
MYC and BCR/ABL1: One of the first oncogenes 
described as activated by chromosomal 
rearrangement is MYC, which was characterised in 
Burkitt lymphoma studies. 
Another example is the translocation between ABL1 
and BCR. Peter Nowell and David Hungerford first 
described a recurrent presence of an extra-
chromosome in CML patients in 1960 (Nowell PCH 
and Hungerford DA, 1960). In 1973 Janet D. Rowley 
used quinacrine coloration to prove this chromosome 
to be the result of a translocation between 
chromosomes 9 and 22 (Rowley JD, 1973a). Only as 
late as 1982 de Klein et al. showed that the genes 
ABL1 and BCR were fused together giving rise to an 
abnormal gene (de Klein A et al., 1982). With these 
new techniques, each chromosome and chromosome 
region could be identified on the basis of their unique 
banding pattern, giving daylight to previously 
undetectable subtle rearrangements. By this 
technique she identified the recurrent translocation 
t(8;21)(q22;q22) (Rowley JD, 1973b). These 
findings evoked interest in the cytogenetic analysis 
of other haematological malignancies. The number 
of reported balanced rearrangements has increased, 
in particular translocations including 
t(8;14)(q24;q32), t(2;8)(p11;q24) and 
t(8;22)(q24;q11) in Burkitt lymphoma (Zech L et al., 
1976 ; Berger R et al., 1979 ; Miyoshi I et al., 1979 ; 
Van Den Berghe H et al., 1979 ), t(4;11)(q21;q23) in 
acute lymphoblastic leukaemia (ALL) (Oshimura M 
et al., 1977 ) t(15;17)(q22;q21) in acute 
promyelocytic leukaemia (APL) (Rowley JD et al., 
1977), and t(14;18)(q32;q21) in follicular lymphoma 
(Rowley JD et al., 1977). During this fruitful period 
the first specific translocation in an animal model 
was found, a mouse plasmacytoma, which is a B cell 
malignancy displaying similar characteristics to 
human Burkitt lymphomas (Ohno S et al., 1979). 
The following decade witnessed a rise in number of 
results from malignant solid tumors, mainly 
sarcomas but also a few carcinomas. Several of the 
aberrations identified were as specific as the ones 
that were previously described in haematological 
cancer: t(2;13)(q36;q14) in alveolar 
rhabdomyosarcoma (ARMS) (Seidal T et al., 1982), 
t(11;22)(q24;q12) in Ewing sarcoma (Aurias A et al., 
1983 ; Turc-Carel C et al., 1983), t(X;1)(p11;q21) in 
Kidney cancer (de Jong B et al., 1986) and 
t(6;9)(q23;p23) in alivary gland tumors (ACC) of the 
salivary glands (Stenman G et al., 1986). Evidence 
was showing that many benign tumors were bearing 
characteristic rearrangements, including reciprocal 
translocations such as t(3;8)(p21;q12) in salivary 
gland adenoma (SGA) (Mark J et al., 1980) and 
t(3;12)(q27;q13) in lipoma (Heim S et al., 1986 ; 
Turc-Carel C et al., 1986). 
Although the vast majority of fusion genes are 
formed by balanced translocations, they can also be 
produced by interstitial deletions. These were first 
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identified in the 1990s, amongst them the fusion 
between genes STIL (STIL/TAL1 interrupting 
locus) in T-ALL (Bernard O et al., 1991). Since then, 
many others where observed with more or less 
extensive deletions, duplications and/or 
amplifications in the breakpoint regions (Barr FG et 
al., 1996 ; Simon MP et al., 1997 ; Sinclair PB et al., 
2000 ; Müller E et al., 2011). Gene fusion can also 
arise from copy number shifts like in the 
aforementioned fusion gene USP16/RUNX1 
(ubiquitin specific peptidase 16 and runt related 
transcription factor 1) in chronic myelomonocytic 
leukemia (Gelsi-Boyer V et al., 2008) and in the 
fusion gene SET/NUP214 (SET nuclear proto-
oncogene and nuclear pore complex protein 
Nup214) in T-ALL (Van Vlierberghe P et al., 2008 ; 
Mullighan CG et al., 2009 ; Santo EE et al., 2012 ; 
Plaszczyca A et al., 2014) (Figure 1). 
Technical developments 
In the late 1970s, various technical developments 
helped in solving what molecular consequences the 
oncogenic chromosomal rearrangements could have. 
These techniques enabled the identification and 
characterisation of genes that were located at  
the breakpoints of chromosomal rearrangements. 
The genes implicated in MPC, Burkitt lymphoma 
and CML proved to be pivotal for the comprehension 
of the mechanism underlying chromosomal 
rearrangements. The engineering of fluorescence in-
situ hybridization (FISH) enabled several 
chromosomal structures to be identified 
simultaneously. This significantly improved the 
location of breakpoints on chromosomes. It also 
considerably reduced the scale of which 
chromosomes could be observed and broadened the 
type of rearrangements that could be observed 
(cryptic rearrangements). The big advantage of the 
FISH technique is that it can also be used for non-
dividing cells (interphase nuclei). FISH probes of a 
specific gene can identify new partner genes, like in 
the case of mixed lineage leukemia (MLL, KMT2A) 
gene (De Braekeleer E et al., 2009; Meyer C et al., 
2013). 
Although cytogenetic analyses are unquestionably 
crucial for the identification of fusion genes and 
rearrangements, there are certain limits to this 
technique. Firstly, revealing chromosome bandings 
requires having access to in-vitro living, dividing 
cells so that metaphases can be observed. Secondly, 
some tumor types can have very complex genomes 
which makes it difficult to understand the full story 
and distinguish the primary aberrations and origin of 
the cancer development from the bulk of the 
rearrangements (Speicher MR and Carter NP, 2005). 
 
 
Figure 1:  Timeline of important discoveries concerning fusion genes, chromosomal rearrangements and the establishment of 
databases regrouping all these chromosomal abnormalities. 
 
In the 1990s, the progress of high throughput tools 
for global genetic analyses, such as array based 
platforms for gene expression and copy number 
profiling, gave rise to new methods for observing 
chromosomal rearrangements. These techniques 
were not ideal either since balanced chromosomal 
rearrangements could pass undetected or the analysis 
of expression profiles could prove to be tricky. On 
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the other hand, they presented a higher level of 
resolution than in chromosome banding and didn't 
require prior cell culturing (Pinkel D and Albertson 
DG, 2005; De Braekeleer E et al., 2014). The first 
novel gene fusion detected with the analysis of gene 
expression pattern of a tumor was the fusion of the 
transcription factor PAX3 gene with the nuclear 
receptor co-activator 1, NCOA1 gene. By focusing 
on genes presenting outlined values of expression, 
the fusions genes implicating the transmembrane 
protease serine 2 gene (TMPRSS2) with two genes 
encoding ETS transcription factors. The first is v-ets 
avian erythroblastosis virus E26 oncogene homolog 
(ERG) and the second is ets variant 1 (ETV1) 
(Tomlins SA et al., 2005). It was the first report of 
specific fusion genes implicated and representing a 
major subset of a common epithelial malignancy. By 
using a modification of this method, other fusion 
genes were discovered in many tumor types, such as 
tenosynovial giant cell tumor, lung cancer and 
chondrosarcoma (West RB et al., 2006; Rikova K et 
al., 2007; Soda M et al., 2007; Wang L et al., 2012). 
The introduction of deep sequencing technologies a 
few years ago gave a new insight to identify new 
fusions genes either at DNA or RNA level. The 
combination of detailed information (base pair level) 
and broad (genome-wide) on DNA, transcriptome, 
structural variants and fusion transcripts could be 
obtained without any prior information on the 
cytogenetic features of the cancer cells. The initial 
study using deep sequencing to detect fusion genes 
or chromosomal rearrangements were done on 
established cell lines (Campbell PJ et al., 2008). The 
analysis of primary samples from common cancer 
(Maher CA et al., 2009a; Maher CA et al., 2009b), 
such as carcinomas of the breast (Stephens PJ et al., 
2009), colon (Cancer Genome Atlas Research 
Network, 2013), lung (Cancer Genome Atlas 
Research Network, 2012), prostate (Cancer Genome 
Atlas Research Network, 2014), uterus ( Cancer 
Genome Atlas Research Network et al., 2013) as 
well as leukaemias and lymphomas (Steidl C et al., 
2011 ; Welch JS et al., 2011 ; Roberts KG et al., 
2012), came afterward. One study draws a bridge 
between over several several cancers by cumulating 
the bioinformatics data of 4,366 cancers from 13 
different tumor types that were previously studied 
within the Cancer Genome Atlas (TCGA) network. 
The outcome was the description of 8,600 different 
fusion transcripts (Yoshihara K et al., 2015). These 
results have dramatically changed the gene fusion 
landscape with the identification of more than 
10,000 fusion genes with more than 90% of these 
having been identified by various deep-sequencing 
approaches during the last 5 years (Mitelman F et al, 
2016; Huret JL et al., 2013). 
The high resolution of deep sequencing gave the 
possibility to identify the vast majority of genes 
implicated in chromosomal rearrangements that 
would have been complicated or impossible to 
identify by conventional cytogenetic techniques. 
Indeed, 75% of the genes fusions first detected by 
deep sequencing are intrachromosomal and 
approximately 50% are between genes located in the 
same chromosome band (Mitelman F et al, 2016). 
Large majority of genes, - already described in the 
literature before the deep sequencing era- were 
embedded in extensive networks like MLL in 
leukaemias, EWS RNA-binding protein 1 (EWSR1) 
in sarcomas and rearranged during Transfection 
Protooncogene (RET) in carcinomas (Mitelman F et 
al., 2007). However, this picture has somewhat 
changed with the massive increase of fusion genes 
that were added with genome-wide studies. The fact 
that these studies were mainly focusing on 
previously uncharacterized tumor types brought a lot 
of new networks emerging from rarer gene fusions 
than leukaemias, lymphomas and sarcomas. 
Furthermore, carcinomas often show highly 
rearranged genomes, with numerous mutations at the 
gene and chromosome levels and it may be that the 
genes detected by deep sequencing are the results of 
chance events caused by chromosomal instability, as 
vast majority of fusion transcripts were associated 
with amplification or deletion events at the DNA 
level (Yoshihara K et al., 2015; Mitelman H et al, 
2016; Huret JL et al., 2013; Mitelman F et al., 2007; 
Kalyana-Sundaram S et al., 2012). Transcription-
induced gene fusion (TIGF) or Trans-TIGF, when 
they happen on different chromosomes, results in the 
fusion of transcripts from non-adjacent genes 
without a corresponding fusion at DNA level 
(Gingeras TR, 2009; Rickman DS et al., 2009; 
Meyer C et al., 2009 ; Hedegaard J et al., 2014). 
Certain have been shown to have no impact, since 
they were expressed in normal tissues like the fusion 
genes JAZF zinc finger 1 (JAZF1)/SUZ12 a 
polycomb repressive complex 2 subunit and PAX3/ 
. Others, implicating the gene MLL, to be the driving 
mutation (Meyer C et al., 2009). 
The prognostic and treatment value of chromosomal 
rearrangements and mutated genes: The high 
correlation between recurrent gene fusions and 
tumor subtypes has made them the ideal maker for 
diagnostic purposes. This correlation is also 
important in treatment stratification, the best 
example being the different fusion of MLL in AML 
(Meyer C et al., 2009). The routine molecular 
strategy to detect these fusion genes is the use of 
cytogenetics, FISH, RT-PCR and deep sequencing. 
The mounting knowledge of the clinical importance 
of gene fusions, as well as various chromosomal 
rearrangements, has gradually led to an increasing 
emphasis on genetic features in the classification of 
tumors. The latest World Health Organisation 
(WHO) classification, translocation and/or gene 
fusion status is mandatory for the diagnosis of some 
types of tumors, such as "AML with 
Internet databases and resources for cytogenetics and 
cytogenomics 





Atlas Genet Cytogenet Oncol Haematol. 222 
 
t(8;21)(q22;q22), RUNX1/RUNX1T1" and "B 
lymphoblastic leukaemia/lymphoma with 
t(5;14)(q31;q32), IL3/IGH". For other cancers, such 
as alveolar soft part sarcoma and synovial sarcoma, 
it is considered as a distinctive defining element of 
the neoplasm (Fletcher CD, 2014; Swerdlow SH et 
al., 2016). Since fusion genes are diagnostic 
markers, they can also be used as markers for 
monitoring minimal residual disease following 
treatment (De Braekeleer E et al., 2014 ; Hokland P, 
Ommen HB and Hokland P, 2011). Currently, this 
strategy is in clinical use mainly for haematological 
disorders but the improvements in the detection and 
enrichment of circulating cancer cells and DNA 
suggest that solid tumors with gene fusions might 
also be monitored in a similar way (Crowley E et al., 
2013; Karabacak NM et al., 2014; Watanabe M et 
al., 2014; Yu KH et al., 2014; Baccelli I et al., 2013). 
It is important to mention that the detection of the 
fusion gene can be used to monitor the progression 
or the relapse of the cancerous cells but it doesn't 
need to be an important actor in the neoplastic 
phenomenon, as long as they are representative and 
specific of the neoplastic cells (Leary RJ et al., 
2010). 
Research on fusion genes paved the way to develop 
specific drugs targeting chimeric proteins. The 
tyrosine kinase inhibitor Imatinib, approved in 2001, 
was the first drug specifically designed to target the 
chimeric protein BCR/ABL1 in CML (Druker BJ et 
al., 2001; Druker BJ et al., 2001) by blocking its 
kinase activity. This drug dramatically improved the 
lifespan and life quality of patients bearing CML. 
The immense success of imatinib spurred interest in 
developing new compounds against the chimeric 
proteins, all of which are kinase inhibitors. Different 
tumors have shown to display various fusions 
involving kinase-encoding genes, such as ALK, 
BRAF, Fibroblast growth factor receptor 3 (FGFR3), 
neurotrophic tyrosine kinase receptor type 1 
(NTRK1), RET and ROS1 (Yoshihara K et al., 2015; 
; Huret JL et al., 2013; Kohno T et al., 2013 ; Shaw 
AT et al., 2013). These fusion genes are occurring at 
low frequencies but if merged they represent a 
considerable number of patients. Stratification 
strategies considering the  
genotype and phenotype of the tumor would 
contribute greatly to identifying patients with these 
very promising treatment targets. Many new 
compounds are currently being tested in clinical 
models althought others have reached the Phase 1 
and Phase 2 stages in clinical trials, for example, 
chromatin modifier such as MLL (MEN1 (Malik R 
et al., 2015), DOT1L (Chen CW et al., 2015), BRD4 
(Dawson MA et al., 2011) or EZH2 (McCabe MT et 
al., 2012; Fillmore CM et al., 2015). 
The need for organising data banks 
Since discovering their involvement in cancer 
initiation, progression and evolvement, 
chromosomal rearrangements have triggered wide, 
increasing interest to understanding them better. The 
amount of genes involved has increased, the network 
underlying certain genes has been resolved and the 
mechanistic aspect is unravelled. Unfortunately, a lot 
of work has to be done before cancer has been 
eradicated. One of the steps is to synthesise all the 
information and make it available in order to 
increase the common knowledge of genes that are 
implicated and their interactions with other pathways 
in the cell. The importance of creating data banks 
and reporting various chromosomal rearrangements 
has been recogniced since the 80's. 
1981: Human Genome Mapping 
The information on chromosome modification in 
cancer has been included as part of the Human 
Genome Mapping (HGM) workshop since 1981. 
The provision of up-to-date information of all 
chromosomal rearrangements was the initial goal. 
This means including all case reports, which are 
suspected to be the starting point of tumor 
development or a contribution to the proliferation 
but also complex karyotypes with several 
cytogenetic anomalies or secondary modifications 
leading to the evolution and resistance to treatment. 
The increasing number of cases, reports and the 
multitude of cytogenetically abnormal neoplasms 
made it too challenging to include everything in the 
database. In 1991, the HGM decided to focus only 
on aberrations repeatedly found as sole anomalies in 
a few given tumor types. As a consequence the 
number of recurrent changes was severely 
underestimated, especially in solid tumors where 
single anomalies are a rare finding. This illustration 
of chromosomal anomalies mainly represents the tip 
of the iceberg since the generalisation and 
improvements in classic cytogenetic techniques and 
the development of new techniques have 
considerably increased the number of reports of 
chromosomal rearrangements in different types of 
tumors. Several of these anomalies may be of 
diagnostic and prognostic importance, as well as a 
large amount of details of molecular analysis. 
 
1983: Catalog of Chromosome Aberrations in 
Cancer 
In 1983, Felix Mitelman published a colossal 
manuscript that was a supplement to Cytogenetics 
and Cell Genetics. The goal of this publication was 
to catalogue all known chromosomal 
rearrangements. The complexity of the data pushed 
the laboratories and institutes to adopt computerised 
methods to compile, revise and index the 
information. Many cytogeneticist, clinicians and cell 
biologists were in the demand for a systematic, 
concise and uniform presentation of material. The 
vast body of literature was making it complicated to 
evaluate if a chromosomal abnormality had been 
described before or not. To facilitate this process, 
Internet databases and resources for cytogenetics and 
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Mitelman presented a compilation of 3,844 
published and unpublished cases from colleagues or 
from his own laboratory. The two volumes presented 
all the implicated genes, chromosomes and 
rearrangements known. This set of two books was 
the first of its kind but far from the last. For several 
years these two volumes accompanied the 
bookshelves of several cytogenetists and 
oncologists. A re-edition of this work took place in 
1985 with data of new cases and improved data of 
cases already described. The number of cases had 
now increased to a bit more than 5,000. The number 
of cases increased with each edition so that by the 
fifth edition it was composed of two large volumes 
of more than 4,000 pages, making it arduous to use. 
The sixth edition had already more than 30,000 cases 
in it. To make it more user friendly it was then 
published as a CD. The number of cases would still 
continue to increase and this information was not 
freely available. Felix Mitelman then had the idea to 
display the information on the Internet, rendering it 
freely available. In 2000, the catalogue became 
accessible for the public under the name Mitelman 
Database of Chromosome Aberrations in Cancer 
associated to the Cancer Genome Anatomy Project 
internet site and under the supervision of the 
National Cancer Institute (see below). 
1997: Atlas of Genetics and Cytogenetics in 
Oncology and Haematology 
How did the idea of the Atlas come about? Prognosis 
for leukaemia depends on the genes involved: 5 
years survival rate: 6% in the inv(3)(q21q26) 
RPN1/MECOM leukemia, 100% in the 
dic(9;12)(p13;p13) PAX5/ETV6 leukemia. 
Treatment depends on the severity of the disease. 
However, thousands of genes were discovered to be 
implicated in cancer (14,000 unique fusion 
transcripts have been detected), and 1,200 types of 
solid tumors exist. Some cancers are frequent while 
many others are very rare (many with only 1 
published case). This is particularly true for 
leukemia subtypes of which there are more than 
1,000! 25,000 new publications concerning human 
cancer genetics are added each year to PubMed. No-
one has the whole required knowledge, necessary to 
guide the treatment procedure in case of a rare 
disease. The following conclusion was made that 
huge databases were required to collect and 
summarize data on these rare diseases in order to 
produce meta-analyses. The Atlas has been 
established for that reason; to contribute to 'meta-
medicine', meaning the mediation between the 
knowledge and the knowledge users in medicine. 
Besides resources dedicated only to cytogenetics, a 
quick overview of resources in surrounding areas 
"Cancer Cytogenetics", stricto sensu, deals with 
chromosomes and cancer. "Cytogenetics" means 
"Cell Genetics" ("cyto" comes from κ υ τ ο ς, in the 
meaning of the term "the cell"); "Cytogenomics", as 
coined by Alain Bernheim, (Bernheim A et al., 2004) 
(from a princeps paper in French in 1998), means the 
"genetics -as a whole- of the cell", with complex 
interconnections and interactions between these 
operators. As is known for long, "one-gene-one-
reaction" (Beadle GW, 1945) (understood today as 
"one-gene-one-protein"), and we can infer from 
"Cyto-genomics" to the terms "Cyto-transcriptome" 
and "Cyto-proteomics", or, in a more holistic 
approach, (and more simply) "Cell Biology". 
Cancer is now known as being a multi-step process, 
with genetic events at almost each step. Therefore, 
the "Cancer Cytogenetics" research field should 
incorporate knowledge of the "Cell Biology" of 
normal and cancerous cells, gene fusions, mutations 
or copy number variation, epigenetics, protein 
domains, metabolic or signaling pathways, as well as 
consequences of these cytogenomic rearrangements 
and disorders in the pathogenesis of cancer, from 
gross and microscopic pathological presentation to 
patients and diseases, clinical pictures, and, even, to 
epidemiological data given by cancer registries. 
It is useful for the cancer cytogeneticists to have an 
easy and quick access to databases and books of 
these surrounding subject areas. Therefore, besides 
resources of cancer cytogenetics, we will mention 
other resources, including resources on proteins and 
resources on cancer. 
Presently, Internet provides access to a vast and 
complex network of knowledge that can make it 
challenging for you to find the answer to your 
questions. Several databases are freely accessible, 
but unfortunately not all of them are user friendly. 
We will briefly describe the main resources in the 
following pages. 
Recent reviews on cancer databases 
In complement, and not to duplicate good recent 
publications in the last months, some reviews on 
cancer databases list most of the Internet resources 
in the general field of cancer genomics. A review of 
L. Chin gives an overview of the current state if 
cancer genomics (L. Chin et al., 2011). Regardless 
of a wide spectrum of references, the topic of 
cytogenetic resources is absent (Pavlopoulou A et 
al., 2015 ; Klonowska K et al., 2016 ; Brookes AJ, 
Robinson PN and Brookes AJ, 2015 ; Yang Y et al., 
2015 ; Niroula A and Vihinen M, 2016 ; Diehl AG 
and Boyle AP, 2016; Martincorena I, et al. 2015). 
There are also many descriptions of database (and 
particularly in cancer) in all special issues of Nucleic 
Acid Reseach (each year in January). 
2. GENERAL RESOURCES 
Note: a detailed description of General resources in 




PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) is 
a widely used and free search engine and database of 
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biomedical citations and abstracts, based essentially 
on the MEDLINE database of references on life 
sciences and biomedical topics. Medline is the U.S. 
National Library of Medicine (NLM) premier 
bibliographic database. PubMed Central 
(http://www.ncbi.nlm.nih.gov/pmc/) is an archive of 
biomedical and life sciences journal literature. 
Articles are deposited by participating journals, as 
well as for author manuscripts that have been 
submitted in compliance with the public access 
policies of participating research funding agencies. 
Scopus (http://www.scopus.com/) is a database 
owned by Elsevier. 
II- Nomenclatures  
Gene Nomenclature: The HUGO Gene 
Nomenclature Committee (HGNC, 
http://www.genenames.org/) is the authority that 
assigns standardised nomenclature to human genes. 
Nomenclature for the description of sequence 
variations (http://www.hgvs.org/mutnomen/) is 
maintained by the Human Genome Variation Society 
(HGVS). International System for Human 
Cytogenetic Nomenclature (ISCN): The ISCN is the 
language used to describe abnormal karyotypes. 
International Classification of Diseases for 
Oncology, 3rd Edition (ICD-O-3): The WHO/OMS 
has established a code, which provides a 
topographical (organ) identifier and an identifier for 
the detailed pathology. 
III- Nucleic acid, genes and protein databases 
Nucleic acid databases: GenBank 
(http://www.ncbi.nlm.nih.gov/genbank/) is a DNA 
sequence database. The need to have (in parallel to 
the genome projects) the best representation of 
genomic and transcript sequences (for diverse 
species) has been at the origin of consensus 
databases (as RefSeq, UCSC, Ensembl) with several 
methods of optimisation. Genomic sequences and 
transcripts: RefSeq 
(http://www.ncbi.nlm.nih.gov/refseq/) maintains 
and curates a database of annotated genomic, 
transcript, and protein sequence records. Ensembl 
(http://www.ensembl.org/) developed a software 
which produces and maintains automatic annotation 
on selected eukaryotic genomes. The UCSC 
Genome Browser database (see above) is a large 
collection containing genome assemblies of various 
species. Proteins: In addition to the amino acid 
sequence, protein name and description with 
domains, these databases may provide a brief 
annotation information, others are only 
computationally analysed. These databases are the 
following: UniProt (http://www.uniprot.org/), a hub 
consisting of two sections: "TrEMBL" and "Swiss-
Prot"; neXtProt (http://www.nextprot.org/db/); 
PhosphoSitePlus 
(http://www.phosphosite.org/homeAction.action), 
an excellent resource providing comprehensive 
information and tools for the study of protein post-
translational modifications; PROSITE 
(http://prosite.expasy.org/) Pfam 
(http://pfam.xfam.org/) and InterPro 
(http://www.ebi.ac.uk/interpro/). The Atlas of 
Genetics and Cytogenetics in Oncology and 
Haematology presents highly curated paragraphs 
with the description of the protein, but on a restricted 
sample. 
IV- Cards 
Entrez Gene (http://www.ncbi.nlm.nih.gov/gene/) is 
NCBI's primary text search and retrieval system that 
integrates the PubMed database and molecular 
databases including DNA and protein sequence, 
structure, gene, genome, genetic variation and gene 
expression. Genecards (http://www.genecards.org/) 
is a database that provides information on all 
annotated and predicted human genes. 
V- Genome cartography  
The cartography of genes on a genome has always 
been a fundamental mean of representation of 
genomic information. With the human Genome 
Project, several types of viewers have been 
developed. To date, two sites are of first interest for 
human genetics: The UCSC Genome Browser 
website (http://genome.ucsc.edu/) contains the 
reference sequence for a large collection of genomes. 
The Genome Browser zooms and scrolls over 
chromosomes, "Blat" quickly maps a sequence to the 
genome. The UCSC Cancer Browser 
https://genome-cancer.ucsc.edu/proj/site/help/) 
allows researchers to interactively explore cancer 
genomics data and its associated clinical 
information. Ensembl (http://www.ensembl.org) 
generates genomic datasets and distributes created 
datasets and promote standards and interoperability 
between genomic resources. 
VI- Structural variation databases 
Genomic structural variation (including insertions, 
deletions, inversions, translocations and locus copy 
number changes) accounts for individual differences 
at the DNA sequence level in humans and can play a 
major role in diseases. Several databases have 
integrated data produced in the literature on copy 
number variation of DNA sequences: dbVar 
(http://www.ncbi.nlm.nih.gov/dbvar/), DGV - 
Genomic Variants 
(http://dgv.tcag.ca/dgv/app/home), DECIPHER 
(https://decipher.sanger.ac.uk/) and 1000 Genomes 
(http://www.1000genomes.org/). 
VII- Polymorphism databases 
It is important to distinguish polymorphisms due to 
single nucleotide (SNP) as the variability within a 
population and mutations acquired in a neoplastic 
process. The determination of variants was 
previously obtained by SNP arrays, but is nowadays 
performed by massive parallel sequencing. 
Polymorphism databases are: dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/overview.html), 
HAPMAP 
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(http://hapmap.ncbi.nlm.nih.gov/index.html.en), 
1000 Genomes Project 
(http://www.1000genomes.org/) and Exome Variant 
server (EVS) (http://evs.gs.washington.edu/EVS/). 
VIII- Portals/Working consortiums  
The primary goals of these projects are to generate 
catalogues of genomic abnormalities (somatic 
mutations, SNP genotyping, copy number variation 
profiling, abnormal expression of genes, epigenetic 
modifications) of series of genes in tumors from 
different cancer types. The main portals are: TCGA 
(http://cancergenome.nih.gov/), ICGC: 
(https://icgc.org/), OASIS (http://www.oasis-
genomics.org/) and Firebrowse 
(http://firebrowse.org/). 
IX- Impact on diseases 
"Online Mendelian Inheritance in Man" (OMIM, 
http://omim.org/) is a catalog of human genes and 
genetic disorders; other databases providing 
information about human disorders and other 




SNPs3D (http://www.snps3d.org/) and GTR 
(http://www.ncbi.nlm.nih.gov/gtr/). 
X- Pathology 
Authoritative books in pathology includes clinical 
features, morphologic, immunohistochemical and 
molecular genetic features and prognosis, with a 
very large iconography. They are the following: the 
"Rosai and Ackerman's Surgical Pathology" and the 
"WHO/IARC Classification of Tumours series" 
(http://publications.iarc.fr/Book-And-Report-
Series/Who-Iarc-Classification-Of-Tumours). The 
Armed Forces Institute of Pathology (AFIP) 
publishes series of the "AFIP Atlas of Tumor 
Pathology". The Atlas of Genetics and Cytogenetics 
in Oncology and Haematology provides complete 
description of diseases, but again on a limited 
sample; on the other hand, articles on genes closely 
related to these diseases are found, right next, in the 
Atlas. As a product of collaborative work, the 
usefulness of the Atlas is dependent on colleague 
participation in updating and completing it. 
PathologyOutlines (http://pathologyoutlines.com/) 
provides iconography. To be also noted, the United 
States and Canadian Academy of Pathology 
(USCAP, http://www.uscap.org/). The International 
Classification of Diseases for Oncology, 3rd Edition 
(ICD-O-3) gives ICD-O codes for each cancer, with 
an ICD-O3-TOPO, which provides a topographical 
(organ) identifier and an ICD-O3-MORPH, which 
provides the basic and detailed pathology. 
XI- Cancer Registries 
Cancer registries are organizations seeking to 
collect, store, analyze, and report data on various 
cancers for epidemiological purposes. The 
International Agency for Research on Cancer 
(IARC, http://www.iarc.fr/) is the specialized cancer 
agency of the World Health Organization 
(WHO/OMS). It publishes the "Cancer Incidence in 
Five Continents" series and GLOBOCAN 
(http://globocan.iarc.fr/Default.aspx). The 
International Association of Cancer Registries 
(IACR, http://www.iacr.com.fr/) has developed 
classifications (the ICD-O), guidelines for registry 
practices and standard definitions. quality control, 
consistency checks and basic analysis of data, 
making data comparable between registries. The 
European Network of Cancer Registries (ENCR, 
http://www.encr.eu/) has the same role in Europe as 
IACR has worldwide. The National Program of 
Cancer Registries (NPC, 
http://www.cdc.gov/cancer/), maintained by the 
Centers for disease control and prevention (CDC), 
collects data on cancer occurrence in the USA. The 
Surveillance, Epidemiology, and End Results 
(SEER, http://seer.cancer.gov/) is a program of the 
National Cancer Institute. To be cited as well, the 
Union for International Cancer Control (UICC, 
http://www.uicc.org/). 
XII- Patient associations and interfaces between 
science and patients - freely accessible services 
Associations of parents and friends of patients: 
These associations of parents of patients with a rare 
disease are precious. They give moral support and 
help, and offer practical guidances and information 
about social benefits, subsidies and day-to-day life to 
families affected by illness. They often establish a 
program of grants for research (e.g. Xeroderma 
Pigmentosum Society (http://www.xps.org/, 
Sarcoma Foundation of America 
(http://www.curesarcoma.org/), Union for 
International Cancer Control (UICC) 
(http://www.uicc.org/)). Interfaces between science 
and patients: These sites provide information for 
patients, including in formation on diseases, 
professionals for genetic counselling, laboratories, 




3. CYTOGENOMICS RESOURCES 
Note: a detailed description of Cancer Cytogenomics 
resources may be found at Cancer Cytogenomics 
resources 
I- Chromosome rearrangements/Hybrid genes 
Mitelman Database:  
The database of chromosome aberrations in cancer 
counts a total number of cases amounting to more 
than 60,000, implicating more than 10,000 gene 
fusions, culled from the literature and organized into 
distinct sub-databases: The "Cases Quick Searcher" 
and the "Cases Full Searcher" contain the data 
related to chromosomal aberrations in individual 
cases. The "Molecular Biology Associations 
Searcher" collects cases according to the gene 
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rearrangements. The "Clinical Associations 
Searcher" is based on tumor characteristics, related 
to chromosomal aberrations and/or gene 
rearrangements. This free access database shows raw 
data and is reliable. 
Atlas of Genetics and Cytogenetics in Oncology 
and Haematology:  
The Atlas (http://atlasgeneticsoncology.org) is a peer 
reviewed on-line journal encyclopaedia and database 
with free access on the Internet. It is an integrated 
structure and comprises the following topics: genes, 
cytogenetics and clinical entities in cancer, and 
cancer-prone diseases. The Atlas combines various 
types of knowledge all on one site: genes, gene 
rearrangements, cytogenetics, protein domains, 
function, cell biology, pathways. It also contains 
clinical genetics, including hereditary diseases 
which are cancer-prone conditions, and diseases, 
focusing on cancers, but also listing other medical 
conditions. The Atlas is mainly composed of 
structured review articles or "cards" (original 
monographs written by invited authors), The Atlas 
contributes to the cytogenetic diagnosis and may 
guide treatment decision makingI 
COSMIC (http://cancer.sanger.ac.uk/cosmic) is a 
catalog of somatic mutations in cancer. It includes all 
abnormalities, from single nucleotide variations to 
chromosome rearrangements / fusion genes. 
Other resources:  
chimerDB 2.0 
http://biome.ewha.ac.kr:8080/FusionGene/ is a 
database of fusion genes with PubMed references 
and some information about the structure of chimeric 
genes. TICdb (http://www.unav.es/genetica/TICdb/) 
is a database of Translocation breakpoints In Cancer 
with the fusion sequences at the nucleotide level. 
ChiTARS (http://chitars.bioinfo.cnio.es/) is a 
database of chimeric transcripts. TCGA Fusion gene 
Data Portal (http://54.84.12.177/PanCanFusV2/) 
presents an analysis across tumor types of the TCGA 
program. Other resources are OMIM 
(http://www.omim.org/, Fusion cancer 
(http://donglab.ecnu.edu.cn/databases/FusionCance
r/). "Cancer Cytogenetics: Chromosomal and 
Molecular Genetic Abberations of Tumor Cells" is a 
book authored by Sverre Heim and Felix Mitelman. 
II- Data for SKY and FISH 
Fluorescence in-situ hybridization (FISH) technique 
enables identification of chromosomal structures to 
be identified using specific probes. This significantly 
improves the localisation of breakpoints on 
chromosomes. FISH technique can also be used on 
non-dividing cells (interphase nuclei). The Cancer 
Chromosome Aberration Project (CCAP) has 
generated a set of BAC clones that have been 
mapped cytogenetically by FISH and physically by 
STSs to the human genome. The BAC data is 
integrated into various databases 
(http://cgap.nci.nih.gov/Chromosomes/CCAPBAC
Clones), (http://mkweb.bcgsc.ca/bacarray/. All BAC 
can be located on the UCSC genome browser 
(http://genome.ucsc.edu). BAC from the fishClones 
file can be visualized on the chromosomal bands on 
the Atlas (http://atlasgeneticsoncology.org/Bands/). 
More recently, several commercial companies have 
developed more specific catalogs of FISH clones as 
oligonucleotides probes. 
III- Comparative genomic hybridization (CGH) 
resources  
This technique detects disequilibria between a 
disease sample and a normal sample. Several sites 
are repositories for these CGH/SNP profiles: GEO, 





(http://cistrome.org/CaSNP/), Cell line project 




IV- Mutation databases 
The determination of variants was previously 
obtained by SNP arrays, but is nowadays performed 
by massive parallel sequencing. As a result, a huge 
quantity of polymorphisms and mutations in tumors, 
are compared to controls. The landscape of the 
majority of recurrent mutations is now known and 
can be used for diagnosis. Even in haematological 
malignancies, where the chromosome 
rearrangements have shown to bear a major role, 
nonetheless, it appears now that some mutations at 
the nucleotide level can still be very important in 
determining treatments in relation to patient outcome 
(e.g. ASXL1, ATM, BCL6, BRAF, KRAS and 
NRAS, CBL, CCND3, CDKN2A and CDKN2C, 
CEBPA, CRLF2, ETV6, FLT3, GATA2, ID3, 
IDH1, IDH2, IKZF1, JAK1, KIT, MYD88, 
NOTCH1, NPM1, RUNX1, TP53). The main 
mutation databases are: COSMIC 
(http://cancer.sanger.ac.uk/cosmic), CENSUS 
(http://cancer.sanger.ac.uk/census/), HGMD  
(http://www.hgmd.cf.ac.uk/ac/index.php), LOVD 
(http://www.lovd.nl/3.0/home), TCGA cBIoPortal 
(http://www.cbioportal.org/), ICGC Data Portal 
(https://dcc.icgc.org/), OASIS Portal (see above), 
IntOGen (http://www.intogen.org), BioMuta v2 
(https://hive.biochemistry.gwu.edu/tools/biomuta/), 
DoCM (http://docm.genome.wustl.edu/), CIViC 
(https://civic.genome.wustl.edu/#/home), and ExAC 
(http://exac.broadinstitute.org). 
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TABLE 1: Internet resources 
  
4. PRACTICAL EXERCISE 
See online Practical Exercices. 
5. DISCUSSION 
We have briefly discussed the various databases 
useful for clinicians, students, and researchers in 
finding answers to their questions and in determining 
which field in cancer research still needs to be 
studied. Only a handful of databases or portals take 
the cytogenetic information into consideration 
although being one of the first observation points 
confirming that the cell has transformed into a 
cancerous cell. Over the years (1960-2016), chimeric 
genes and fusion proteins have been discovered 
mainly by cytogenetic means. This has led to 
understanding of major cancerogenetic processes, 
and, later on, to the concept of treatments targets for 
many cases. Cytogenetics, or rather, cytogenomics 
of cancer, is a major contributor for the concept of 
"personalized medicine for cancer", together with 
other tools for other mechanisms.  
Dorothy Warburton wrote her colleagues in the 
American Cytogenetics Forum List: Subject: Is 
Cytogenetics Dying? "I have been told by my 
department chairman and other advisers that 
cytogenetics is dying at least three times: in 1968 
(just before banding), in 1984 (just before FISH) and 
in 2001 (just before microarrays) (...) Chromosome 
changes are being recognised as the cause of more 
and more abnormalities, not fewer. This is true for 
both cancer and constitutional cytogenetics (...) 
There are also a great many basic facts about how 
chromosome abnormalities originate that we know 
little about and that are great fields for research". 
Besides what is known, there is still a lot to learn 
about how a mutation or a chromosomal 
rearrangement is influencing the cellular 
mechanism. 
A decade ago, conventional wisdom was that the 
expressed genes were regulating all the processes in 
the cell and the rest of the genome was considered as 
"junk DNA".  
The main purpose of this junk DNA was to act as a 
buffer and to protect the coding part from any kind 
of aggression. Progressively, we realized that the 
mutations happening outside the coding regions 
could influence the expression of nearby genes or in 
some cases several kilobases away. These mutations 
were located in regulatory regions recruiting or 
blocking transcription factors binding DNA. 
More elements were found in the "junk DNA" with 
the discovery of the microRNAs (miRNA) and long 
non-coding RNAs (lincRNA). Both proved 
influential in regulating the genome and the 
expression of several genes.  
These miRNA and lincRNA are deregulated during 
the carcinogenic process and studies have 
demonstrated that by re-establishing the normal 
expression of one or few miRNAs or lincRNAs, the 
cancer cells transform back into normal cells. 
Afterwards, it was observed that genes which were 
not mutated could be silenced and vice versa. This 
was due to the epigenetic regulation of the genes and 
the recruitment of epigenetic regulators in  
 
different regions of the genome.  
The cancerous cells actively modify their own 
epigenetic marks on the genome to increase the 
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expression of stemness genes providing them with 
proliferative or resistance advantages. 
The chromosome structure in the nucleus is 
dependent on many variables modulating the 
chromatin interactions across the whole genome. 
Techniques like chromatin conformation capture and 
interphase fluorescent in situ hybridization (FISH) 
detect spatial associations between specific genes. In 
the future, they are likely to be the techniques for 
detecting abnormalities associated with progression 
of tumours. Similarly, when modifying the 3D 
structure of chromosomes, it has been demonstrated 
that the disruption of chromosome neighbourhoods 
via mutations in insulated neighbourhood 
boundaries (cohesin CTCF interactions) activates 
proto-oncogenes in cancer cells (Hnisz D et al., 
2016). 
As mentioned above, the last build of the human 
genome (GRCh38, Dec 2013) is more precise than 
the previous ones and takes into account more 
haplotypes shared by parts of the human population. 
Nevertheless, due to a great part of repeated 
sequences of various classes (50% of the genome), 
there are some gene families only present at low 
frequencies, e.g. the insertions of endogenous 
retroviruses, which represent 8% of the genome and 
are mostly not localized on GRCh38 for a great part 
(Wildschutte JH et al., 2016). We need to recognize 
that such a diversity may be a factor leading to 
susceptibility to cancer or other diseases. 
There is an increasing realisation that our 
environment, our nutrition and our way of life have 
an impact on how our cells mutate and how theses 
mutations are repaired or how the abnormal cells are 
eliminated by our organism. 
It is difficult to fully understand and appreciate the 
complexity of the cellular mechanism and the 
various levels that can be deregulated in cancer 
makes. The use of databases makes this process 
easier as it condenses the complex information and 
provides links to other relevant databases providing 
even more specialized information. 
Sequencing of thousands of genomes of patients 
bearing different types of tumours and genomes of 
normal persons, generates a huge amount of data 
demonstrating the complexity of tumours. Focus 
points are the sensitive parts of the genome which 
are more prone to be mutated, the expression 
profiles, the function of the proteins, the pathways 
the proteins are located in, and the protein 
interactions (in normal cases and abnormal cases). 
The same is done at the single cell level, bringing a 
huge amount of data demonstrating the 
heterogeneity of the tumour and the interaction with 
the niche. In principle, this wealth of integrated 
genomic data and clinical information could reveal 
the genetic bases of cancer, inherited diseases, and 
drug responses-illnesses and remedies that have 
touched nearly every person and family across the 
globe. This will constitute the databases of 
tomorrow. 
Interpreting these data requires a larger evidence 
base than any one party alone can develop. However, 
existing technologies, regulations and approaches 
are currently not designed for sharing and 
interpreting this wealth of information effectively, 
especially across diseases and nations. Databases 
will need to integrate information increasingly in the 
upcoming years but also stay interoperable with 
other databases. This corroborates the idea of having 
a common nomenclature and language to avoid 




https://genomicsandhealth.org) in the same manner 
in which the Working Group for Planetary System 
Nomenclature maintains the "astronomical naming 
conventions and planetary nomenclature", any 
scientific field, confronted with the exponential 
growth of data, has to create a system of 
classification and thesaurus for naming of new items, 
and nosological definitions. This often implies the 
use of a structured grammar and census of accepted 
terms/objects. 
Resources such as the International System for 
Human Cytogenetic Nomenclature (ISCN), the 
International Classification of Diseases for 
Oncology (ICD-O), the Human Gene Nomenclature 
Database (HGNC), and the Nomenclature for the 
description of sequence variations (from the HGVS) 
are indispensable research tools allowing a common 
language. 
Interoperability: In the context of interoperability 
between recent cancer projects, such as TCGA and 
ICGC as well as all data produced by thousands 
laboratories or hospitals, the Global Alliance for 
Genomics and Health (Global Alliance, 
https://genomicsandhealth.org/) (Lawler M et al., 
2015) was created to accelerate the potential of 
genomic medicine. This association brings together 
over 375 leading institutions working together to 
generate a common framework of harmonized 
approaches in enabling the data sharing. In 
particular, it works to establish interoperable 
technical standards (standardised language and 
tools) to management of genomic and clinical data 
and for a better representation of genotype-
phenotype associations. 
Open data (open source, open hardware, open 
content, and open access) is a concept so dear to 
many, in particular in the medical and scientific 
world. This concept has recently had a renewed 
vigour with/since the advent of the Internet. 
Maintaining the data open and free remains a daily 
struggle. Everything has a cost, even a free database, 
from upkeeping and updating the database to 
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providing for the scientific staff necessary to 
produce expertized data. 
Data should remain freely available. However, a 
business model remains to be established. Although 
economic investment by the public sector would 
benefit the whole of mankind, as well as 
economically profitable in the end, most of the 
institutional stakeholders are gradually disengaging, 
and well-known databases are forced to beg for 
funds (see recent examples, useless to cite them!) or 
to disappear. This would be a regrettable drawback 
for the scientific and medical community - yet it may 
still happen. 
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